Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 1:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 156 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Steatohepatitis Caused by Ingestible Alcohol Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant

NCT05553470
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
Miricorilant
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Rialto, California • Miami, Florida • Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH

NCT02784444
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, NASH - Nonalcoholic Steatohepatitis
Interventions
MSDC-0602K, Placebo
Drug
Lead sponsor
Cirius Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
43
States / cities
Chandler, Arizona • Tucson, Arizona • Chula Vista, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 11, 2026, 1:19 PM EDT
Recruiting Phase 3 Interventional

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

NCT06632444
View directory record Official record
Conditions
Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Interventions
Survodutide, Placebo
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
165
States / cities
Birmingham, Alabama • Peoria, Arizona • Scottsdale, Arizona + 132 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of Icosabutate in Fatty Liver Disease

NCT04052516
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis (NASH)
Interventions
Icosabutate, Placebo
Drug
Lead sponsor
NorthSea Therapeutics B.V.
Industry
Eligibility
18 Years to 75 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
38
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis

NCT00680407
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis
Interventions
Placebo, Silymarin 700 mg, Silymarin 420 mg
Other · Drug
Lead sponsor
Madaus Inc
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
6
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Phase 3 Interventional Results available

Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)

NCT00063622
View directory record Official record
Conditions
Liver Diseases
Interventions
Pioglitazone, Vitamin E, Matching placebo
Drug · Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
8
States / cities
San Diego, California • San Francisco, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 11, 2026, 1:19 PM EDT
Terminated Phase 3 Interventional Results available

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment

NCT02548351
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis (NASH)
Interventions
Obeticholic Acid, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
175
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 116 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Phase 2 Interventional

Treatment of Nonalcoholic Steatohepatitis With Pioglitazone

NCT00013598
View directory record Official record
Conditions
Fatty Liver, Nonalcoholic Steatohepatitis
Interventions
Pioglitazone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224

NCT04932512
View directory record Official record
Conditions
Steatohepatitis, Nonalcoholic
Interventions
ION224, Placebo
Drug · Other
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
50
States / cities
Chandler, Arizona • Glendale, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis

NCT01766713
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis
Interventions
Ezetimibe
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 11, 2026, 1:19 PM EDT
Recruiting No phase listed Observational

Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease

NCT05728697
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Obesity
Interventions
Endoscopic ultrasound shear wave elastography
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

NCT06052566
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Hepatic Impairment
Interventions
Efinopegdutide
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Miami, Florida • Tampa, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects

NCT02612662
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
AZD4076, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Phase 1 Interventional

Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis

NCT01899859
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis (NASH)
Interventions
GR-MD-02, Placebo
Drug
Lead sponsor
Galectin Therapeutics Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 11, 2026, 1:19 PM EDT
Completed No phase listed Observational

Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease

NCT02520609
View directory record Official record
Conditions
Liver Disease, Fatty Liver
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 11, 2026, 1:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of Leptin Receptors in NASH

NCT00583999
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Metabolic Syndrome
Interventions
no interventions, only regular blood-draw
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

NCT03969719
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis
Interventions
Placebo, PF-06835919
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
86
States / cities
Gilbert, Arizona • Tempe, Arizona • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Biomarkers of Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis Following Bariatric Surgery

NCT03294850
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver Disease
Interventions
Bariatric surgery, HepQuant SHUNT Dual Cholate Liver Diagnostic Kit
Procedure · Device
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 11, 2026, 1:19 PM EDT
Terminated No phase listed Observational

Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics

NCT00375011
View directory record Official record
Conditions
Cirrhosis
Interventions
Not listed
Lead sponsor
Meridian Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 11, 2026, 1:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease

NCT06176079
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non Alcoholic Steatohepatitis, NAFLD, NASH
Interventions
Hyperpolarized (HP) 13C, Hyperpolarized 13C-Urea, Magnetic Resonance Imaging, Saline Flush
Drug · Procedure
Lead sponsor
Michael Ohliger, MD PhD
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 11, 2026, 1:19 PM EDT
Terminated Phase 2 Interventional Results available

Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)

NCT03883607
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis
Interventions
Elafibranor 80mg, Elafibranor 120mg
Drug
Lead sponsor
Genfit
Industry
Eligibility
8 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
San Diego, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 11, 2026, 1:19 PM EDT
Withdrawn Phase 1 Interventional

A Pilot, Dose Escalating Study on VLX103 in Moderate Alcoholic Steatohepatitis

NCT03201159
View directory record Official record
Conditions
Hepatic Steatosis
Interventions
VLX103
Drug
Lead sponsor
Gyongyi Szabo
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability of Oral Proglumide for NASH

NCT04152473
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Proglumide
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 11, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver

NCT00323414
View directory record Official record
Conditions
Fatty Liver
Interventions
Polyunsaturated fatty acid (Opti-EPA), Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 11, 2026, 1:19 PM EDT